Computational drug repositioning based on side-effects mined from social media

Drug repositioning methods attempt to identify novel therapeutic indications for marketed drugs. Strategies include the use of side-effects to assign new disease indications, based on the premise that both therapeutic effects and side-effects are measurable physiological changes resulting from drug intervention. Drugs with similar side-effects might share a common mechanism of action linking side-effects with disease treatment, or may serve as a treatment by “rescuing” a disease phenotype on the basis of their side-effects; therefore it may be possible to infer new indications based on the similarity of side-effect profiles. While existing methods leverage side-effect data from clinical studies and drug labels, evidence suggests this information is often incomplete due to under-reporting. Here, we describe a novel computational method that uses side-effect data mined from social media to generate a sparse undirected graphical model using inverse covariance estimation with l1-norm regularization. Results show that known indications are well recovered while current trial indications can also be identified, suggesting that sparse graphical models generated using side-effect data mined from social media may be useful for computational drug repositioning. Subjects Bioinformatics, Data Mining and Machine Learning, Computational Biology, Social Computing

[1]  Tariq Ahmad,et al.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci , 2010, Nature Genetics.

[2]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[3]  Yang Yang,et al.  Use of Genome-Wide Association Studies for Cancer Research and Drug Repositioning , 2015, PloS one.

[4]  F. Reinholt,et al.  Osteopontin--a possible anchor of osteoclasts to bone. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Bo Luo,et al.  Mining Adverse Drug Reactions from online healthcare forums using Hidden Markov Model , 2014, BMC Medical Informatics and Decision Making.

[6]  Jie Li,et al.  Prediction of Polypharmacological Profiles of Drugs by the Integration of Chemical, Side Effect, and Therapeutic Space , 2013, J. Chem. Inf. Model..

[7]  C. Carter,et al.  Peripheral oxytocin is associated with reduced symptom severity in schizophrenia , 2010, Schizophrenia Research.

[8]  Taha A. Kass-Hout,et al.  Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter , 2014, Drug Safety.

[9]  Richard B. Berlin,et al.  Predicting adverse drug events from personal health messages. , 2011, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[10]  Ping Zhang,et al.  Exploring the Relationship Between Drug Side-Effects and Therapeutic Indications , 2013, AMIA.

[11]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[12]  Mátyás A. Sustik,et al.  GLASSOFAST : An efficient GLASSO implementation , 2012 .

[13]  W. Inman,et al.  Under-reporting of adverse drug reactions. , 1985, British medical journal.

[14]  C. Nemeroff,et al.  Ziprasidone in the treatment of mania in bipolar disorder , 2007, Neuropsychiatric disease and treatment.

[15]  Ping Zhang,et al.  Exploring the associations between drug side-effects and therapeutic indications , 2014, J. Biomed. Informatics.

[16]  G. Gimpl,et al.  Cholesterol and steroid hormones: modulators of oxytocin receptor function. , 2002, Progress in brain research.

[17]  P. Robinson,et al.  Walking the interactome for prioritization of candidate disease genes. , 2008, American journal of human genetics.

[18]  C. O’Brien Statistical Learning with Sparsity: The Lasso and Generalizations , 2016 .

[19]  K. Hatanaka,et al.  Meloxicam Inhibits Prostaglandin E2 Generation via Cyclooxygenase 2 in the Inflammatory Site but Not That via Cyclooxygenase 1 in the Stomach , 2000, Pharmacology.

[20]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[21]  Azadeh Nikfarjam,et al.  Mining Twitter for Adverse Drug Reaction Mentions : A Corpus and Classification Benchmark , 2014 .

[22]  Olivier Ledoit,et al.  Honey, I Shrunk the Sample Covariance Matrix , 2003 .

[23]  Richard T Owen Ramelteon: profile of a new sleep-promoting medication. , 2006, Drugs of today.

[24]  Péter Csermely,et al.  A unified data representation theory for network visualization, ordering and coarse-graining , 2014, Scientific Reports.

[25]  Collectif Side Effects of Drugs Annual : A worldwide yearly survey of new data in adverse drug reactions , 2015 .

[26]  Guanghui Hu,et al.  Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.

[27]  Paloma Martínez,et al.  Exploring Spanish health social media for detecting drug effects , 2015, BMC Medical Informatics and Decision Making.

[28]  Alexandre d'Aspremont,et al.  Model Selection Through Sparse Max Likelihood Estimation Model Selection Through Sparse Maximum Likelihood Estimation for Multivariate Gaussian or Binary Data , 2022 .

[29]  T. Mjörndal,et al.  Under‐reporting of serious adverse drug reactions in Sweden , 2004, Pharmacoepidemiology and drug safety.

[30]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. , 2004, Diabetes care.

[31]  Allen C. Browne,et al.  Identifying Consumer-Friendly Display (CFD) Names for Health Concepts , 2005, AMIA.

[32]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[33]  V. Khajuria,et al.  Under-reporting of adverse drug reactions: A challenge for pharmacovigilance in India , 2015, Indian journal of pharmacology.

[34]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[35]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[36]  Jeffrey Dean,et al.  Efficient Estimation of Word Representations in Vector Space , 2013, ICLR.

[37]  R. Tibshirani,et al.  Sparse inverse covariance estimation with the graphical lasso. , 2008, Biostatistics.

[38]  E. Ladenheim Liraglutide and obesity: a review of the data so far , 2015, Drug design, development and therapy.

[39]  Jian Yang,et al.  Towards Internet-Age Pharmacovigilance: Extracting Adverse Drug Reactions from User Posts in Health-Related Social Networks , 2010, BioNLP@ACL.

[40]  N. Meinshausen,et al.  High-dimensional graphs and variable selection with the Lasso , 2006, math/0608017.

[41]  A. Minassian,et al.  Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia Patients , 2010, Biological Psychiatry.

[42]  Cécile Paris,et al.  Text and Data Mining Techniques in Adverse Drug Reaction Detection , 2015, ACM Comput. Surv..

[43]  K. Rainsford,et al.  Effects of Meloxicam, Compared with other NSAIDs, on Cartilage Proteoglycan Metabolism, Synovial Prostaglandin E2, and Production of Interleukins 1, 6 and 8, in Human and Porcine Explants in Organ Culture , 1997, The Journal of pharmacy and pharmacology.

[44]  Marc Reisch On the auction block , 2006 .

[45]  Alexander A. Morgan,et al.  Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.

[46]  Abeed Sarker,et al.  Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features , 2015, J. Am. Medical Informatics Assoc..

[47]  S. Picksley,et al.  Human hair follicles contain two forms of ATP‐ sensitive potassium channels, only one of which is sensitive to minoxidil , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  F. Scheer,et al.  Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. , 2013, Journal of affective disorders.

[49]  Patrick Aloy,et al.  Recycling side-effects into clinical markers for drug repositioning , 2012, Genome Medicine.

[50]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[51]  Philip E. Bourne,et al.  Predicting the Polypharmacology of Drugs: Identifying New Uses through Chemoinformatics, Structural Informatics, and Molecular Modeling‐Based Approaches , 2012 .

[52]  H. Ghofrani,et al.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.

[53]  K. Strimmer,et al.  Statistical Applications in Genetics and Molecular Biology A Shrinkage Approach to Large-Scale Covariance Matrix Estimation and Implications for Functional Genomics , 2011 .

[54]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[55]  Ji Hoon Kim,et al.  Delay in the Recovery of Normal Sleep-Wake Cycle after Disruption of the Light-Dark Cycle in Mice: A Bipolar Disorder-Prone Animal Model? , 2014, Psychiatry investigation.

[56]  Pankaj Agarwal,et al.  Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.

[57]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[58]  S. Tuck,et al.  Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis , 2011, Osteoporosis International.

[59]  George Hripcsak,et al.  Similarity-based modeling in large-scale prediction of drug-drug interactions , 2014, Nature Protocols.

[60]  Hao Ye,et al.  Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning , 2014, PloS one.

[61]  Xiaowei Xu,et al.  Investigating drug repositioning opportunities in FDA drug labels through topic modeling , 2012, BMC Bioinformatics.

[62]  Trevor J. Hastie,et al.  Exact Covariance Thresholding into Connected Components for Large-Scale Graphical Lasso , 2011, J. Mach. Learn. Res..

[63]  P. Sanseau,et al.  Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.

[64]  P. Tak,et al.  Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis , 2011, Annals of the rheumatic diseases.

[65]  Abeed Sarker,et al.  Portable automatic text classification for adverse drug reaction detection via multi-corpus training , 2015, J. Biomed. Informatics.

[66]  Z. Cao,et al.  Mining drug–disease relationships as a complement to medical genetics‐based drug repositioning: Where a recommendation system meets genome‐wide association studies , 2015, Clinical pharmacology and therapeutics.

[67]  T. Gilliam,et al.  Molecular triangulation: bridging linkage and molecular-network information for identifying candidate genes in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Roded Sharan,et al.  Associating Genes and Protein Complexes with Disease via Network Propagation , 2010, PLoS Comput. Biol..

[69]  R. Altman,et al.  Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.

[70]  Alexander E. Ivliev,et al.  Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach , 2013, PloS one.

[71]  D. Penn,et al.  Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia , 2011, Schizophrenia Research.

[72]  E. Tobinick The value of drug repositioning in the current pharmaceutical market. , 2009, Drug news & perspectives.

[73]  Y. Nakaya,et al.  Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. , 2001, The Journal of investigative dermatology.

[74]  D. Feifel Oxytocin as a Potential Therapeutic Target for Schizophrenia and Other Neuropsychiatric Conditions , 2012, Neuropsychopharmacology.

[75]  Gary D. Bader,et al.  Cytoscape Web: an interactive web-based network browser , 2010, Bioinform..

[76]  D. Feifel,et al.  Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating , 1999, Psychopharmacology.

[77]  Patrick Danaher,et al.  The joint graphical lasso for inverse covariance estimation across multiple classes , 2011, Journal of the Royal Statistical Society. Series B, Statistical methodology.

[78]  Massimiliano Pontil,et al.  PSICOV: precise structural contact prediction using sparse inverse covariance estimation on large multiple sequence alignments , 2012, Bioinform..

[79]  W. Li,et al.  The p38-MAPK/SAPK pathway is required for human keratinocyte migration on dermal collagen. , 2001, The Journal of investigative dermatology.

[80]  E. Lopez-Gonzalez,et al.  Determinants of Under-Reporting of Adverse Drug Reactions , 2009, Drug safety.

[81]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[82]  D. Dorsa,et al.  Social Interaction Deficits Caused by Chronic Phencyclidine Administration are Reversed by Oxytocin , 2005, Neuropsychopharmacology.

[83]  Hong-yu Zhang,et al.  Rational drug repositioning by medical genetics , 2013, Nature Biotechnology.